Results 81 to 90 of about 7,043,555 (280)

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study) [version 2; peer review: 1 approved, 2 approved with reservations]

NIHR Open Research
Background In adults, treatment of GHD with daily GH injection has been shown to improve many clinical features associated with GHD. Currently, many adults with GHD receive GH treatment indefinitely.
Niki Karavitaki, Sherwin Criseno, Anne Topping   +2 more
doaj   +1 more source

Immunofunctional assay of human growth hormone (hGH) in serum: A possible consensus for quantitative hGH measurement [PDF]

, 1996
Confirmation of the diagnosis of GH deficiency in adults and children involves provocative testing for human (h) GH. Different commercially available immunoassays yield largely discrepant results in the measurement of GH levels in human serum.
Strasburger, Christian J., Pflaum, Claus-Dieter, Dressendörfer, Regina A., Wu, Zida   +3 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

The effects of Growth hormone treatment discontinuation in Adults on Metabolic profile, Body composition and quality Of Life (GAMBOL Study) [version 1; peer review: 1 approved, 2 approved with reservations]

NIHR Open Research
Background In adults, treatment of growth hormone deficiency with daily recombinant human growth hormone injections has shown to improve many clinical features associated with GHD.
Niki Karavitaki, Sherwin Criseno, Anne Topping   +2 more
doaj   +1 more source

Cognitive function in patients with childhood-onset combined pituitary hormone deficiency not treated with growth hormone

Journal of Medical Science, 2016
Introduction. Growth hormone deficiency is a known factor leading to impairment of psychological performance but there are very few studies on cognitive function in adult patients with childhood-onset combined pituitary hormone deficiency (ChO-CPHD ...
Izabela Warmuz-Stangierska, Monika Gołąb, Adam Stangierski, Małgorzata Kałużna, Elvira Rak, Tamara Nowocień, Marek Ruchała, Katarzyna Ziemnicka   +7 more
doaj   +1 more source

Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee [PDF]

, 1998
"GH DEFICIENCY in the human adult most commonly results from pituitary or peripituitary tumors and their treatment (1). The majority of these tumors are benign, and in a large series, pituitary adenoma was the commonest cause of adult hypopituitarism (2).
Tanaka, T, Sonksen, P.H., Christiansen, J.S., Hintz, R., Thorner, M., Bengtsson, B A, Laron, Z., Clemmons, D, Ho, K., Carlsson, L., Sizonenko, P, Christ, E R, Hintz, R, Sönksen, P H, Carlsson, L, Carroll, P V, Sizonenko, P., Tanaka, T., Carroll, Paul V., Laron, Z, Thorne, M, Sizonenko, Pierre-Claude, Christiansen, J S, Ho, K, Clemmons, David, Christ, Emanuel R., Bengtsson, B.A.   +26 more
core   +2 more sources

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Genetic regulation of pituitary gland development in human and mouse [PDF]

, 2009
Normal hypothalamopituitary development is closely related to that of the forebrain and is dependent upon a complex genetic cascade of transcription factors and signaling molecules that may be either intrinsic or extrinsic to the developing Rathke’s ...
Robin Lovell-Badge, Dattani, M. T., Robinson, I. C. A. F., Mehul T. Dattani, Lovell-Badge, R., Karine Rizzoti, Iain C. A. F. Robinson, Rizzoti, K., Kelberman, D., Daniel Kelberman   +9 more
core   +1 more source